Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CCM.0000000000006815 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Managing hypermobility spectrum disorder in a psychiatric setting.
BMJ Case Rep
March 2025
Psychiatry and Behavioral Neuroscience, SSMHealth/SLUCare Physician Group, St Louis, Missouri, USA.
This case highlights the intersection of psychiatric symptoms and hypermobility spectrum disorder (HSD) in a woman in her 20s with multiple comorbidities, including postural orthostatic tachycardia syndrome, chronic pain and obstructive sleep apnoea. The patient had been unresponsive to conventional psychiatric treatments for anxiety and panic attacks. On recognition of HSD, a multidisciplinary approach, including propranolol for autonomic dysfunction, pregabalin for pain and anxiety, and lisdexamfetamine for cognitive impairment, significantly improved her condition.
View Article and Find Full Text PDFPropranolol As an Anxiolytic to Reduce the Use of Sedatives for Critically Ill Adults Receiving Mechanical Ventilation (PROACTIVE): An Open-Label Randomized Controlled Trial.
Crit Care Med
February 2025
Hamilton Health Sciences, Hamilton, ON, Canada.
Objectives: Surges in demand for sedatives for mechanical ventilation during the COVID-19 pandemic caused shortages of sedatives globally. Propranolol, a nonselective beta-adrenergic blocker, has been associated with reduced agitation and sedative needs in observational studies. We aimed to test whether propranolol could reduce the dose of sedatives needed in mechanically ventilated patients.
View Article and Find Full Text PDFBeta-blockers for the treatment of anxiety disorders: A systematic review and meta-analysis.
J Affect Disord
January 2025
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Background: Beta-blocker prescriptions for patients with anxiety increased substantially between 2003 and 2018, yet there is no clinical guidance concerning their use. A previous review of propranolol - a beta-blocker - in the treatment of anxiety concluded there was insufficient evidence to support its use. Additional data have been published in the eight years since that review including some evidence for other beta-blockers.
View Article and Find Full Text PDFNo harmful effect of propranolol administered prior to fear memory extinction in rats and humans.
J Anxiety Disord
June 2024
Centre for Psychology of Learning and Experimental Psychopathology, Faculty of Psychology and Educational Sciences, KU Leuven, Leuven, Belgium; Leuven Brain Institute, KU Leuven, Leuven, Belgium. Electronic address:
Exposure therapy is an evidence-based treatment option for anxiety-related disorders. Many patients also take medication that could, in principle, affect exposure therapy efficacy. Clinical and laboratory evidence indeed suggests that benzodiazepines may have detrimental effects.
View Article and Find Full Text PDF